Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2005-01-31
2010-02-02
Rao, Deepak (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C514S252190, C514S275000, C544S122000, C544S295000, C544S331000
Reexamination Certificate
active
07655652
ABSTRACT:
Compounds of the formula (I), wherein variable groups are as defined within and a pharmaceutically acceptable salts and in vivo hydrolysable esters are described. Also described are processes for their preparation and their use as medicaments, particularly medicaments for producing a cell cycle inhibitory (anti cell proliferation) effect in a warm blooded animal, such as man.
REFERENCES:
patent: 4983608 (1991-01-01), Effland et al.
patent: 5516775 (1996-05-01), Zimmermann et al.
patent: 5521184 (1996-05-01), Zimmermann
patent: 5610303 (1997-03-01), Kimura et al.
patent: 5739143 (1998-04-01), Adams et al.
patent: 5859041 (1999-01-01), Liverton et al.
patent: 6835726 (2004-12-01), Cushing et al.
patent: 2003/0144303 (2003-07-01), Hawley et al.
patent: 2003/0191307 (2003-10-01), Blumenkopf et al.
patent: 2006/0079543 (2006-04-01), Sum et al.
patent: 2231765 (1998-09-01), None
patent: 0135472 (1989-01-01), None
patent: 0363002 (1994-06-01), None
patent: 0379806 (1996-04-01), None
patent: 1056742 (2003-07-01), None
patent: 0945443 (2003-08-01), None
patent: 220630 (2002-03-01), None
patent: WO 91/18887 (1991-12-01), None
patent: WO 92/20642 (1992-11-01), None
patent: WO 95/09847 (1995-04-01), None
patent: WO 95/09851 (1995-04-01), None
patent: WO 95/09852 (1995-04-01), None
patent: WO 95/09853 (1995-04-01), None
patent: WO 95/15952 (1995-06-01), None
patent: WO 96/05177 (1996-02-01), None
patent: WO 96/28427 (1996-09-01), None
patent: WO 96/40143 (1996-12-01), None
patent: WO 97/19065 (1997-05-01), None
patent: WO 97/35856 (1997-10-01), None
patent: WO 97/40017 (1997-10-01), None
patent: WO 97/44326 (1997-11-01), None
patent: WO 9747618 (1997-12-01), None
patent: WO 98/11095 (1998-03-01), None
patent: WO 98/16230 (1998-04-01), None
patent: WO 98/18782 (1998-05-01), None
patent: WO 98/25619 (1998-06-01), None
patent: WO 98/33798 (1998-08-01), None
patent: WO 98/41512 (1998-09-01), None
patent: WO 98/54093 (1998-12-01), None
patent: WO 98/56788 (1998-12-01), None
patent: WO 99/01136 (1999-01-01), None
patent: WO 99/18096 (1999-04-01), None
patent: WO 99/18942 (1999-04-01), None
patent: WO 99/31073 (1999-06-01), None
patent: WO 99/32121 (1999-07-01), None
patent: WO 99/41253 (1999-08-01), None
patent: WO 99/50250 (1999-10-01), None
patent: WO 99/50251 (1999-10-01), None
patent: WO 00/12485 (2000-03-01), None
patent: WO 00/12486 (2000-03-01), None
patent: WO 00/17202 (2000-03-01), None
patent: WO 00/17203 (2000-03-01), None
patent: WO 00/21926 (2000-04-01), None
patent: WO 00/25780 (2000-05-01), None
patent: WO 00/26209 (2000-05-01), None
patent: WO 00/39101 (2000-06-01), None
patent: WO 00/44750 (2000-08-01), None
patent: WO 00/49018 (2000-08-01), None
patent: WO 00/53595 (2000-09-01), None
patent: WO 00/55161 (2000-09-01), None
patent: WO 00/59892 (2000-10-01), None
patent: WO 00/78731 (2000-12-01), None
patent: WO 01/14375 (2001-03-01), None
patent: WO 01/29009 (2001-04-01), None
patent: WO 01/30778 (2001-05-01), None
patent: WO 01/37835 (2001-05-01), None
patent: WO 01/47897 (2001-07-01), None
patent: WO 01/47921 (2001-07-01), None
patent: WO 01/60816 (2001-08-01), None
patent: WO 01/64653 (2001-09-01), None
patent: WO 01/64654 (2001-09-01), None
patent: WO 01/64655 (2001-09-01), None
patent: WO 01/64656 (2001-09-01), None
patent: WO 01/72717 (2001-10-01), None
patent: WO 02/04429 (2002-01-01), None
patent: WO 02/20512 (2002-03-01), None
patent: WO 02/46170 (2002-06-01), None
patent: WO 02/46171 (2002-06-01), None
patent: WO 02/65979 (2002-08-01), None
patent: WO 02/066480 (2002-08-01), None
patent: WO 02/66481 (2002-08-01), None
patent: WO 02/92573 (2002-11-01), None
patent: WO 02/96887 (2002-12-01), None
patent: WO 02/96888 (2002-12-01), None
patent: WO 03/007955 (2003-01-01), None
patent: WO 03/011837 (2003-02-01), None
patent: WO 03/029249 (2003-04-01), None
patent: WO 03/031446 (2003-04-01), None
patent: WO 03/037891 (2003-05-01), None
patent: WO 03/076433 (2003-09-01), None
patent: WO 03/076434 (2003-09-01), None
patent: WO 03/076435 (2003-09-01), None
patent: WO 03/076436 (2003-09-01), None
patent: WO 2004/005282 (2004-01-01), None
patent: WO 2004/005283 (2004-01-01), None
patent: WO 2004/043467 (2004-05-01), None
patent: WO 2004/043953 (2004-05-01), None
patent: WO 2004/087698 (2004-10-01), None
patent: WO 2004/087699 (2004-10-01), None
patent: WO 2004/101549 (2004-11-01), None
patent: WO 2004/101564 (2004-11-01), None
patent: WO 2005/012298 (2005-02-01), None
patent: WO 2005/037800 (2005-04-01), None
patent: WO 2005/068452 (2005-07-01), None
patent: WO 2005/075468 (2005-08-01), None
patent: WO 2005/113550 (2005-12-01), None
patent: WO 2005/116025 (2005-12-01), None
patent: WO 2006/034872 (2006-04-01), None
patent: WO 2006/044509 (2006-04-01), None
patent: WO 2006/050076 (2006-05-01), None
patent: WO 2006/064251 (2006-06-01), None
patent: WO 2006/075152 (2006-07-01), None
patent: WO 2006/095159 (2006-09-01), None
patent: WO 2007/015064 (2007-02-01), None
patent: WO 2007/036732 (2007-04-01), None
patent: WO 2007/040436 (2007-04-01), None
patent: WO 2007/040440 (2007-04-01), None
patent: WO 2007/138268 (2007-12-01), None
patent: WO 2007/138277 (2007-12-01), None
patent: WO 2007/148070 (2007-12-01), None
patent: WO 2008/002244 (2008-01-01), None
patent: WO 2008/002245 (2008-01-01), None
Banker et al., Prodrugs, Modern Pharmaceutics, Third Edition, Revised and Expanded, pp. 451 and 596.
Bundgaard, Design of Prodrugs, p. 1, 1985.
Wolff, Some consideration for prodrug design, Burger's Medicinal Chemistry and Drug Discovery, 5th Edition, vol. I: Principles and Practice, pp. 975-977, 1995.
Traxler, Protein tyrosine kinase inhibitors in cancer treatment, Expert Opinion on Therapeutic Patents, 7(6), pp. 571-588, 1997.
Lu Valle et al., Cell Cycle Control in Growth Plate Chondrocytes, Frontiers in Biosciences 5, d493-503, May 2000.
Fiziol Akt Veshchestva 7:68-72 (1975) (Translation enclosed).
Blain, S. et al. “Differential interaction of the cyclin-dependent kinase (Cdk) inhibitor p27Kip1with cyclin A-Cdk2 and cyclin D2-Cdk4” The Journal of Biological Chemistry, 1997, vol. 272, No. 41, pp. 25863-25872.
Boschelli, D. et al. “Synthesis and tyrosine kinase inhibitory activity of a series of 2-amino-8H-pyrido[2,3-d]pyrimidines: identification of potent, selective platelet-derived growth factor receptor tyrosine kinase inhibitors” J. Med. Chem., 1998, vol. 41, pp. 4365-4377.
Deady L. et al. “Reactions of some quinazoline compounds with ethoxymethylenemalonic acid derivatives” J. Heterocyclic Chem., 1989, vol. 26, pp. 161-168.
El-Kerdawy, M. et al. “2,4-Bis(substituted)-5-nitropyrimidines of expected diuretic action” Egypt. J. Chem., 1986, 29, vol. 2, No. 2, pp. 247-251.
Fiziol Alct Veshchestva, 1975, 7, pp. 68-72.
Ghosh, D. et al. “2,4-Bis(arylamino)-5-methylpyrimidines as antimicrobial agents” J. Med. Chem., 1967, vol. 10, pp. 974-975.
Ghosh, D., “2,4-Bis(arylamino)-6-methyl pyrimidines as antimicrobial agents” Chemical Abstracts, 1981, vol. 95, No. 11, Columbus, Ohio, US; Abstract No. 97712f; pp. 648; XP002109184 abstract & J. Indian Chem. Soc., 1981, vol. 58, No. 5, pp. 512-513, India.
Schmidt, H. et al. “A convenient synthesis of 2-substituted 4-amino-5-pyrimidinecarbonitriles” J. Heterocyclic Chem., 1987, vol. 24, pp. 1305-1307.
Simone, J. “Oncology: introduction” Bennett, J. Textbook of Medicine, 20th Edition, vol. 1, 1996, pp. 1004-1010.
Volin, M. et al. “Cell cycle implications in the pathogenesis of rheumatoid arthritis” Frontiers in Bioscience, 2000, 5, d594-601.
Zimmermann, J. et al. “Phenylamino-pyrimidine (PAP) derivatives: a new class of potent and selective inhibitors of protein kinase C (PKC)” Arch. Pharm. Pharm. Med. Chem. 1996, 329 (7), pp. 371-376.
Anderson et al, “Imidazo[1,2-a]pyridines: A potent and selective class of cyclin-dependent kinase inhibitors identified through structure-based hybridisation” Bioorganic & Medicinal Chemistry Letters 13(18):3021-3026 (2003).
Byth et al. “Imidazo[1,2-a]pyridin
Andrews David Michael
Finlay Maurice Raymond
Green Clive
AstraZeneca AB
Morgan & Lewis & Bockius, LLP
Rao Deepak
LandOfFree
Imidazolo-5-yl-2-anilinopyrimidines as agents for the... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Imidazolo-5-yl-2-anilinopyrimidines as agents for the..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Imidazolo-5-yl-2-anilinopyrimidines as agents for the... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4217512